1398p -35.0 -2.4%
Last Trade - 27/05/20
| Market Cap | £3.10bn |
| Enterprise Value | £3.08bn |
| Revenue | £273.4m |
| Position in Universe | 197th / 1828 |
| Industry | Market | |
|---|---|---|
|
|
|
|
|
|
|
|
|
|
|
| Year End 31st Dec | 2014 | 2015 | 2016 | 2017 | 2018 | 2019 | TTM | 2020E | 2021E | CAGR / Avg |
|---|---|---|---|---|---|---|---|---|---|---|
|
x
|
||||||||||
| Profitability | ||||||||||
|
%
|
||||||||||
|
%
|
||||||||||
|
%
|
||||||||||
| Cashflow | ||||||||||
| Dividends | ||||||||||
| Balance Sheet | ||||||||||
|
m
|
||||||||||
|
m
|
||||||||||
|
m
|
||||||||||
| Leverage (ttm) | Total | - Intang | + Pension |
|---|---|---|---|
| Gross Gearing % | |||
| Net Gearing % | |||
| Cash / Assets % |
| Liquidity (ttm) | ||
|---|---|---|
| Curr. Ratio | ||
| Quick Ratio | ||
| Interest Cov. | ||
| Efficiency (ttm) | ||
|---|---|---|
| Asset Turnover | ||
| Recs Turnover | ||
| Stock Turnover | ||
| Latest interim period vs. prior period | Industry | Market |
|---|---|---|
|
|
|
|
|
|
|
| 3yr Compound Annual Growth Rate | Industry | Market |
|---|---|---|
|
|
|
|
|
|
|
|
|
|
|
Revenue
Net Income
Normalised EPS
PE Ratio Range
Dividend Yield Range
|
Price Target:
( below Price)
|
31st Dec 2020
|
31st Dec 2021
|
||||
|---|---|---|---|---|---|---|
| Est. Long Term Growth Rate: |
Net Profit () |
EPS () |
DPS () |
Net Profit () |
EPS () |
DPS () |
| Consensus Estimate | ||||||
| 1m Change | ||||||
| 3m Change | ||||||
Abcam plc is a global life sciences company. As a developer of reagents and tools, the Company's purpose is to serve life science researchers globally. Providing the research and clinical communities with tools and scientific support, the Company offers validated biological binders and assays to address important targets in critical biological pathways. The Company is engaged in data sharing and ecommerce in the life sciences. The Company focuses on helping advance global understanding of biology and causes of disease, which, in turn, will drive new treatments and improved health. Two-thirds of the world's 750,000 life science researchers use its affinity binders, reagents, biomarkers and assays and the Company's products are mentioned in over 20,000 of the 56,000 peer-reviewed papers published each year in the life sciences. It has approximately 10 locations located in the world, through life science research hubs, enabling local services and multi-language support.
| Last Annual | June 30th, 2019 |
| Last Interim | December 31st, 2019 |
| Incorporated | February 12, 1998 |
| Public Since | November 3, 2005 |
| No. of Shareholders: | n/a |
| No. of Employees: | 1,155 |
| Sector | Healthcare |
| Industry | Pharmaceuticals |
| Index | FTSE Aim All Share , FTSE Aim 100 , FTSE Intl-aim UK 50 , , |
| Exchange | London Stock Exchange (AIM) |
| Shares in Issue | 216,152,577 |
| Free Float | (0.0%) |
| Eligible for |
ISAs
SIPPs
|
| Address | Discovery Drive,Cambridge Biomedical Campus Hills Road, CAMBRIDGE, CB20AX, United Kingdom |
| Web | http://www.abcam.com/ |
| Phone | +44 1223 696000 |
| Contact | James Staveley (Vice President - Investor Relations) |
| Auditors | PricewaterhouseCoopers LLP |
As of 27/05/20, shares in Abcam are trading at 1398p, giving the company a market capitalisation of £3.10bn. This share price information is delayed by 15 minutes.
Shares in Abcam are currently trading at 1398p and the price has moved by 0.77% over the past 365 days. In terms of relative price strength - which takes into account the overall market trend - the Abcam price has moved by 21.48% over the past year.
Of the analysts with advisory recommendations for Abcam, there are there are currently 0 "buy" , 6 "hold" and 1 "sell" recommendations. The overall consensus recommendation for Abcam is Sell. You can view the full broker recommendation list by unlocking its StockReport.
Abcam is scheduled to issue upcoming financial results on the following dates:
The Abcam dividend yield is 0.85% based on the trailing twelve month period.
Last year, Abcam paid a total dividend of 0.12, and it currently has a trailing dividend yield of 0.85%. Looking ahead, Abcam has not announced an ex-dividend date yet.
Abcam has yet to annouce their ex-dividend date. The historic dividend yield on Abcam shares is currently 0.85%.
To buy shares in Abcam you'll need a share-dealing account with an online or offline stock broker. Once you have opened your account and transferred funds into it, you'll be able to search and select shares to buy and sell. You can use Stockopedia’s share research software to help you find the the kinds of shares that suit your investment strategy and objectives.
Shares in Abcam are currently trading at 1398p, giving the company a market capitalisation of £3.10bn.
Here are the trading details for Abcam:
Based on an overall assessment of its quality, value and momentum, Abcam is currently classified as a High Flyer. The classification is based on a composite score that examines a wide range of fundamental and technical measures. Stock are classified on the the following spectrum: Super Stocks, High Flyers, Contrarians, Turnarounds, Neutral, Value Traps, Momentum Traps, Falling Stars, and Sucker Stocks. For more information, learn about our StockRank Styles.
Shares in Abcam are currently priced at 1398p. At that level they are trading at 12.33% premium to the analyst consensus target price of 1,244.55.
Analysts covering Abcam currently have a consensus Earnings Per Share (EPS) forecast of 0.25379 for the next financial year.
An important predictor of whether a stock price will go up is its track record of momentum. Price trends tend to persist, so it's worth looking at them when it comes to a share like Abcam. Over the past six months, the relative strength of its shares against the market has been 33.1%. At the current price of 1398p, shares in Abcam are trading at 14.82% against their 200 day moving average. You can read more about the power of momentum in assessing share price movements on Stockopedia.
The Abcam PE ratio based on its reported earnings over the past 12 months is 40.32. The shares are currently trading at 1398p.
The PE ratio (or price-to-earnings ratio) is the one of the most popular valuation measures used by stock market investors. It is calculated by dividing a company's price per share by its earnings per share.
The PE ratio can be seen as being expressed in years, in the sense that it shows the number of years of earnings which would be required to pay back the purchase price, ignoring inflation. So in general terms, the higher the PE, the more expensive the stock is.
Abcam's management team is headed by:
Here are the top five shareholders of Abcam based on the size of their shareholding:
